ABT - Should Abbott and DexCom Investors Be Worried About Apple's Latest News?
Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) enjoy symbiotic relationships with Apple (NASDAQ: AAPL) . The two companies' popular continuous glucose monitoring (CGM) devices used by many patients with diabetes connect to iPhones and Apple Watches. Patients can easily monitor their glucose and receive alerts when thresholds are exceeded on their smart devices.
But that relationship could be about to change significantly in a way that isn't helpful to the two big CGM makers. Bloomberg reported last week about one of Apple's major development efforts. Should Abbott and DexCom investors be worried about Apple's latest news?
Image source: Getty Images.
For further details see:
Should Abbott and DexCom Investors Be Worried About Apple's Latest News?